Display options
Cite
Borg JJ, Tomasi P, Pani L, et al. Licensing of Generic Medicines: Are There Any Challenges Left? A Pharmaceutical Regulatory Perspective. Sci Pharm. 2014;82(4):847-56doi: 10.3797/scipharm.1312-10.
Borg, J. J., Tomasi, P., Pani, L., Aislaitner, G., Pirozynski, M., Leufkens, H., & Melchiorri, D. (2014). Licensing of Generic Medicines: Are There Any Challenges Left? A Pharmaceutical Regulatory Perspective. Scientia pharmaceutica, 82(4), 847-56. https://doi.org/10.3797/scipharm.1312-10
Borg, John Joseph, et al. "Licensing of Generic Medicines: Are There Any Challenges Left? A Pharmaceutical Regulatory Perspective." Scientia pharmaceutica vol. 82,4 (2014): 847-56. doi: https://doi.org/10.3797/scipharm.1312-10
Borg JJ, Tomasi P, Pani L, Aislaitner G, Pirozynski M, Leufkens H, Melchiorri D. Licensing of Generic Medicines: Are There Any Challenges Left? A Pharmaceutical Regulatory Perspective. Sci Pharm. 2014 May 22;82(4):847-56. doi: 10.3797/scipharm.1312-10. Print 2014. PMID: 26171329; PMCID: PMC4475802.
Copy Download .nbib Format: NLM
Share it on

Sci Pharm. 2014 May 22;82(4):847-56. doi: 10.3797/scipharm.1312-10. Print 2014.

Licensing of Generic Medicines: Are There Any Challenges Left? A Pharmaceutical Regulatory Perspective.

Scientia pharmaceutica

John Joseph Borg, Paolo Tomasi, Luca Pani, George Aislaitner, Michal Pirozynski, Hubert Leufkens, Daniela Melchiorri

Affiliations

  1. Medicines Authority, 203 Level 3, Rue D'Argens, Gzira, GZR 1368, Malta. ; Department of Biology, School of Pharmacy, University of Tor Vergata, Rome, Italy.
  2. European Medicines Agency, 7 Westferry Circus, London E14 4HB, UK.
  3. Italian Medicines Agency, AIFA, Via del Tritone, 181, 00186 Rome, Italy.
  4. National Organisation of Medicines (EOF), 284 Messogion STF, 155 62 Athens, Greece.
  5. Department of Anaesthesiology and Critical Care Medicine, Postgraduate MedicalSchool, Czerniakowska 231, 00 416 Warsaw, Poland.
  6. Medicines Evaluation Board (MEB), Graadt van Roggenweg 500, 3531 AH Utrecht, Netherlands.
  7. Department of Physiology and Pharmacology, University of Rome "Sapienza", Rome, Italy.

PMID: 26171329 PMCID: PMC4475802 DOI: 10.3797/scipharm.1312-10

Abstract

When an innovative product (innovator) is not covered anymore by intellectual property rights, cheaper equivalent medicinal products (generic products) may be marketed and used in clinical practice. The regulation of generic products is well-established, and is primarily based on standard rules for quality, therapeutic equivalence requirements (the latter in most instances proven through a bioequivalence study), and safety data for the innovator. The extensive experience from bringing generic products to the market over the last decades allows the conclusion that they are well-accepted and provide a useful alternative option for cost-effective pharmacotherapy. While supporting this conclusion, there are a number of issues to be considered during the assessment of a generic product application. Six scenarios are described in total, from an efficacy and a safety perspective, where potential concerns with the current regulatory standards could arise in the approval of generic products. We also propose solutions to these scenarios in order to foster debate on these issues.

Keywords: Biocreep; Generics; Off-patent medicines; Regulatory science; Safety of generics; Therapeutic equivalence

References

  1. Curr Neurol Neurosci Rep. 2009 Jul;9(4):333-7 - PubMed
  2. BMC Pharmacol Toxicol. 2013 Apr 23;14:24 - PubMed
  3. Epilepsia. 2007 Mar;48(3):464-9 - PubMed
  4. Neurology. 2009 Jun 16;72(24):2122-9 - PubMed
  5. Pharmacotherapy. 2012 Apr;32(4):314-22 - PubMed
  6. J Neurooncol. 2010 May;98(1):137-41 - PubMed
  7. Neurology. 2008 May 27;70(22 Pt 2):2179-86 - PubMed
  8. Neurology. 2004 Oct 26;63(8):1494-6 - PubMed
  9. Parkinsonism Relat Disord. 2011 Jun;17(5):308-12 - PubMed
  10. BMJ. 2013 May 30;346:f3536 - PubMed
  11. Neuropsychiatr Dis Treat. 2008 Aug;4(4):743-57 - PubMed
  12. Epilepsy Res. 2011 Jun;95(1-2):158-67 - PubMed
  13. Curr Control Trials Cardiovasc Med. 2000;1(1):19-21 - PubMed
  14. Clin Ther. 2007 Feb;29(2):334-41 - PubMed
  15. Neurology. 2008 Aug 12;71(7):525-30 - PubMed

Publication Types